These preliminary, positive trial data are very encouraging. The blood viral load reduction data are consistent with BIT225 having an impact on viral reservoirs. Current cART is efficient at rapidly and durably reducing virus levels in the blood, but this does not translate into clearance of long-lived reservoirs of HIV-1. “. “The observed changes to immune markers and cells further the results from the previous BIT225-009 trial and SUGGESTS the utility of targeting VIROPORINS as a NEW CLASS of ANTIVIRAL DRUGS
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-45
-
- There are more pages in this discussion • 131 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
